BamSEC and AlphaSense Join Forces
Learn More

Clearside Biomed – Material Contracts

Formerly OTC: CLSDQ

Material Contracts Filter

EX-10.7
from 10-Q 14 pages Omnibus Amendment Agreement
12/34/56
EX-10.6
from 10-Q 10 pages Consulting Agreement
12/34/56
EX-10.5
from 10-Q 22 pages July 17, 2025 via Email Victor Chong Re: Separation Agreement Dear Victor: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) Which Clearside Biomedical, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1
12/34/56
EX-10.4
from 10-Q 10 pages Consulting Agreement
12/34/56
EX-10.3
from 10-Q 22 pages July 17, 2025 via Email Charlie Deignan Re: Separation Agreement Dear Charlie: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) Which Clearside Biomedical, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1
12/34/56
EX-10.2
from 10-Q 10 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 23 pages July 17, 2025 via Email George Lasezkay Re: Separation Agreement Dear George: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) Which Clearside Biomedical, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1
12/34/56
EX-10.2
from 10-Q 12 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Amendment 1 to the License Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Clearside Biomedical, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective March 14, 2024
12/34/56
EX-10.35
from 10-K 5 pages First Amendment to Consulting Agreement
12/34/56
EX-10.33
from 10-K 6 pages Fourth Amendment to the License Agreement
12/34/56
EX-10.31
from 10-K 62 pages License Agreement by and Between Biocryst Pharmaceuticals, Inc. and Clearside Biomedical, Inc. November 1, 2023
12/34/56
EX-10.2
from 8-K 9 pages Placement Agency Agreement
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 4 pages Reference Is Hereby Made to (I) That Certain Purchase and Sale Agreement, Dated as of August 8, 2022 (As Amended to Date, the “Purchase Agreement”), by and Among Clearside Royalty LLC, a Delaware Limited Liability Company (“Seller”), Healthcare Royalty Partners IV, L.P. a Delaware Limited Partnership (“Purchaser”), and Hcr Clearside Spv, LLC (As Assignee of Hcr Collateral Management, LLC) (“Agent”, and Together With Seller and Purchaser, Each a “Party”, and Collectively, the “Parties”) and (II) That Certain Escrow Agreement, Dated as of August 8, 2022 (As Amended to Date, the “Escrow Agreement”) by and Among Seller, Agent and U.S. Bank National Association (“Escrow Agent”). Capitalized Terms Used Herein and Not Otherwise Defined Herein Shall Have the Meanings Given to Such Terms in the Purchase Agreement. This Letter Agreement (This “Letter Agreement”) Is Being Entered Into by and Among Purchaser, Seller and Agent to Confirm the Agreement Among the Parties as to Certain Matters Relating to the Purchase Agreement and the Escrow Agreement. Now, Therefore, for Good and Valuable Consideration, the Receipt and Sufficiency of Which Is Hereby Acknowledged, the Parties Hereto Hereby Agree as Follows: 1. First Milestone Payment. (A) Notwithstanding Anything to the Contrary in the Purchase Agreement, Seller Desires To, and Hereby Does, Waive Any and All Rights as to the First Milestone Payment. Purchaser and Agent Hereby Acknowledge and Accept Such Waiver
12/34/56
EX-10.1
from 8-K 42 pages Clearside Biomedical, Inc. Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-10
from 10-K 6 pages Amendment No. 1 to the Option and License Agreement
12/34/56
EX-10
from 10-K 11 pages First Amendment to Office Lease Agreement
12/34/56
EX-10
from 8-K 12 pages Clearside Biomedical, Inc. Consulting Agreement Effective Date: February 17, 2023
12/34/56